Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms
- PMID: 14984503
- DOI: 10.1111/j.1365-2141.2004.04804.x
Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms
Abstract
Intravenous (IV) anti-D and IV immunoglobulin (IVIG) slow the Fcgamma receptor (FcgammaR)-mediated destruction of antibody-coated platelets in patients with immune thrombocytopenic purpura (ITP). This pilot study explored the mechanism of these immunoglobulin preparations by measuring interleukin-10 (IL-10), monocyte chemoattractant protein-1 (MCP-1), IL-6 and tumour necrosis factor alpha (TNFalpha), before and after infusion and by assessing the effect of FcgammaRIIa and FcgammaRIIIa polymorphisms on both cytokine and haematologic responses to anti-D. Following IVIG, only IL-10 was increased at 2 h and MCP-1 on day 7 (P < 0.05). In contrast, 2 h after anti-D infusion, plasma levels of all four cytokines were increased (P < 0.01); five of six patients with the highest MCP-1, IL-6 and TNFalpha levels had chills. Higher IL-10 levels correlated with platelet increases at 24 h and haemoglobin decreases at day 7 (P < 0.025). Patients with the FcgammaRIIa-131HH genotype had significantly higher MCP-1, IL-6 and TNFalpha levels. Patients with the FcgammaRIIIa-158VF genotype had higher platelet increments at day 7 (P < 0.05). Soluble CD16 (sCD16) was increased 2 h after IV anti-D; day 7 levels correlated with day 7 haemoglobin decreases (P < 0.01). In conclusion, the relationship of FcgammaRIIa and FcgammaRIIIa polymorphisms with both cytokine levels and platelet increments implicated these receptors in responses to anti-D and supported different mechanisms of FcgammaR interaction to those seen with IVIG.
Similar articles
-
Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.Blood. 2011 May 26;117(21):5723-32. doi: 10.1182/blood-2010-11-321398. Epub 2011 Mar 9. Blood. 2011. PMID: 21389318 Free PMC article.
-
Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.Lancet. 1994 Sep 10;344(8924):703-7. doi: 10.1016/s0140-6736(94)92205-5. Lancet. 1994. PMID: 7915773 Clinical Trial.
-
Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura.Transfus Sci. 1998 Sep;19(3):279-88. doi: 10.1016/s0955-3886(98)00042-3. Transfus Sci. 1998. PMID: 10351140
-
Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action.Transfus Sci. 1998 Sep;19(3):289-94. doi: 10.1016/s0955-3886(98)00043-5. Transfus Sci. 1998. PMID: 10351141 Review.
-
Treatment of immune thrombocytopenic purpura in children : current concepts.Paediatr Drugs. 2005;7(5):325-36. doi: 10.2165/00148581-200507050-00004. Paediatr Drugs. 2005. PMID: 16220997 Review.
Cited by
-
Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.Clin Exp Immunol. 2008 Oct;154(1):1-5. doi: 10.1111/j.1365-2249.2008.03735.x. Epub 2008 Aug 22. Clin Exp Immunol. 2008. PMID: 18727626 Free PMC article. Review.
-
Targeted Therapies for Autoimmune Bullous Diseases: Current Status.Drugs. 2018 Oct;78(15):1527-1548. doi: 10.1007/s40265-018-0976-5. Drugs. 2018. PMID: 30238396 Review.
-
Reactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism.Clin Exp Immunol. 2005 Oct;142(1):92-102. doi: 10.1111/j.1365-2249.2005.02903.x. Clin Exp Immunol. 2005. PMID: 16178861 Free PMC article.
-
Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.Blood. 2011 May 26;117(21):5723-32. doi: 10.1182/blood-2010-11-321398. Epub 2011 Mar 9. Blood. 2011. PMID: 21389318 Free PMC article.
-
RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).Transfusion. 2012 May;52(5):1126-36; quiz 1125. doi: 10.1111/j.1537-2995.2011.03384.x. Epub 2011 Oct 7. Transfusion. 2012. PMID: 21981825 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous